News

The 2025 BIO Asia–Taiwan Exhibition, held from July 24 to 27 at the 4th floor of Taipei Nangang Exhibition Center, spotlights the theme “Next Wave of Biotech Opportunities.” National Chung Hsing University (NCHU) presents a robust lineup of achievements through its Research Commercialization Platform, integrating innovations from faculty and student startups, R&D results, and partner companies to highlight Taiwan’s biotech innovation, R&D capacity, and global competitiveness.

NCHU’s exhibit features diverse highlights across agricultural technology, medical innovation, animal health, functional foods, and smart medical devices—demonstrating strong interdisciplinary integration and academia-industry collaboration. Notable technologies include:

• Postharvest Preservation for Produce by Prof. Chang-Wei Hsieh’s team, which combines microbubble cleaning, intelligent sorting, and biomimetic packaging to replace chemical pesticides and reduce pest detection rates—enhancing export readiness.

• Black and Red Nutrition Power by Assoc. Prof. Yu-Tang Tung’s team, focusing on super grains like black soybeans and Chenopodium formosanum as key health-promoting ingredients for functional food development.

Startup teams under the NCHU platform include:

• Dubo Animal Blood Bank, offering safe and convenient animal blood transfusion solutions.

• Sing U Technology, showcasing a non-invasive bone density detection system with 6-second results, no radiation, and clinical accuracy.

• Gradior, providing fumigation technology to eliminate hidden pests in fresh produce.

• Daily Good Dairy, combining science and taste to create functional dairy products from high-quality ingredients.

NCHU-incubated companies include:

• Adimmune Corporation, a leading biopharmaceutical developer aligned with global GMP standards and actively seeking strategic partners.

• Anterogen, offering a highly protective enterovirus vaccine proven to exceed 99% efficacy in clinical trials.

• Universal Stem Cells, founded on technology by Prof. Hung-Lin Su, using purified autologous mononuclear cells for cell therapy, showing strong results in relieving pain and restoring mobility in osteoarthritis patients.

• ReHope by Prof. Ching-Chou Wu’s team, featuring a non-invasive mitochondrial function assay platform for selecting optimal embryos in IVF, improving implantation success rates.

• Hexon Technology, specializing in precision electroformed nebulizer membranes, offering heat-resistant, corrosion-resistant, and long-lifespan components for various nebulizer applications.

Platform member Changhua Christian Hospital developed an AI-assisted dialysis vascular access prediction system to prevent blockages and reduce complications. In the NSTC-funded Central Taiwan Intercollegiate Research Commercialization Platform, partner Hungkuang University developed a miRNA-200b thermo-sensitive gel to accelerate diabetic wound healing. Taichung Veterans General Hospital introduced an incentive-driven lung function testing device with built-in buffer and one-way microfluidic tubes to simplify sample processing.

Through this exhibition, NCHU not only demonstrates its strong research and commercialization capabilities but also extends an open invitation for global partnerships. Companies interested in biotech innovation are welcome to join NCHU’s Research Commercialization Platform to expand international markets and shape a new future for the biotech industry together.

Article source: https://www2.nchu.edu.tw/news-detail/id/60061